. 2017 Aug 1;14(4):2992–2998. doi: 10.3892/etm.2017.4860

Table I.

Effect of baicalein on endometrial stromal cell viability.

	Cell viability (relative to control)

	24 h		48 h		72 h

Baicalein (µM)	Median	P₂₅-P₇₅	Median	P₂₅-P₇₅	Median	P₂₅-P₇₅
0	1.000	1.000–1.000	1.000	1.000–1.000	1.000	1.000–1.000
5	0.939^a	0.831–0.985	0.978^a	0.922–0.991	0.937^a	0.902–0.987
10	0.897^a	0.801–0.957	0.856^a	0.728–0.933	0.904^a	0.763–0.928
20	0.814^a	0.686–0.913	0.739^a	0.618–0.843	0.841^a	0.571–0.914
40	0.730^a	0.632–0.905	0.654^a	0.575–0.764	0.776^a	0.538–0.844
80	0.603^a	0.511–0.874	0.543^a	0.417–0.740	0.590^a	0.431–0.798
160	0.541^a	0.424–0.692	0.402^a	0.295–0.597	0.454^a	0.284–0.511

Statistical comparisons were made using the Kruskal-Wallis test.

P<0.05 vs. control group (0 µM baicalein). P₂₅, 25th percentile; P₇₅, 75th percentile.